Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat Before Prostatectomy in Prostate Cancer
NCT05567679Phase 1Withdrawn
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat in prostate cancer (PCa). Primary endpoints: Incidence of adverse events, serious adverse events, and treatment-related adverse events, Proportion of patients able to undergo surgery and 2 more. Planned start Dec 2023; status: withdrawn.
02
Drugs
tazemetostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05567679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567679.